FEROX STRATEGIES

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 17, 2026

Lobbying activity 3

Taxation/Internal Revenue Code

General issues related to rare disease treatment development.

Health Issues

General issues related to rare disease treatment.

Trade (domestic/foreign)

General issues related to tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.